Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
The prognosis of hepatitis delta infections in Belgium is poor and determined by the hepatitis delta viremia
E Ho,Liesbeth Govaerts,Peter Michielsen,Thomas Sersté,Jean Delwaide,Stefan Bourgeois,Christophe Moreno,Hans Van Vlierberghe,C. De Galocsy,Hans Orlent,Michael J. Peeters,Elizaveta Padalko,Steven Van Gucht,Thomas Vanwolleghem +13 more
Management of alcohol‐related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines
Alexandre Louvet,Jean-Baptiste Trabut,Christophe Moreno,Romain Moirand,Henri-Jean Aubin,Line Carolle Ntandja Wandji,Mikail Nourredine,Massih Ningarhari,Nathalie Ganne-Carrié,Georges-Philippe Pageaux,François Bailly,Jérôme Boursier,Jean-Bernard Daeppen,Amandine Luquiens,Eric Nguyen-Khac,Rodolphe Anty,Thomas Orban,Hélène Donnadieu-Rigole,Ariane Mallat,Christophe Bureau,Emile-Alexandre Pariente,Thierry Paupard,Amine Benyamina,Pascal Perney,Philippe Mathurin,Benjamin Rolland +25 more
TL;DR: The French Association for the Study of the Liver wished to organise guidelines together with the French Alcohol Society in order to summarise the best evidence available about several key clinical points in ARLD.
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks
Jordan J. Feld,Christophe Moreno,Roger Trinh,Edward Tam,Suzanne Bourgeois,Yves Horsmans,Magdy Elkhashab,David E. Bernstein,Ziad Younes,Robert Reindollar,Lois Larsen,Bo Fu,Kevin Howieson,Akshanth R. Polepally,Andreas Pangerl,Nancy S. Shulman,Fred Poordad +16 more
TL;DR: The HCV regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir without ribavirin for 12weeks achieved 100% SVR12 and was well tolerated in HCV genotype 1b-infected patients with cirrhosis, suggesting that this 12-week ribvirin-free regimen is sufficient in this population.